NCT01184287 is a Phase 2 clinical trial of Ranpirnase in Non-Small Cell Lung Cancer, sponsored by Tamir Biotechnology, Inc..

Who is sponsoring NCT01184287?

NCT01184287 is sponsored by Tamir Biotechnology, Inc..

What drugs are being tested in NCT01184287?

Interventions in NCT01184287: Ranpirnase.

What condition does NCT01184287 study?

NCT01184287 studies Non-Small Cell Lung Cancer.

Is NCT01184287 still recruiting?

NCT01184287 is currently withdrawn. Last updated 2 September 2015.

Last reviewed 2015-09-02 · How we verify

NCT01184287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Withdrawn Phase 2 Last updated 2 September 2015

What this trial tests

Phase 2 trial testing Ranpirnase in Non-Small Cell Lung Cancer. Withdrawn.

Quick facts

Lead sponsor	Tamir Biotechnology, Inc.
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Sites	6 locations across United States

Drugs / interventions tested

Ranpirnase — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Tamir Biotechnology, Inc.

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed-carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ribonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells.
Mironova NL, Petrushanko IY, Patutina OA, Sen'kova AV, et al · · 2013 · cited 27× · PMID 23759588 · DOI 10.4161/cc.25164
Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases.
Mironova N, Vlassov V. · · 2019 · cited 3× · PMID 31572192 · DOI 10.3389/fphar.2019.01019

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01184287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tamir Biotechnology, Inc.
Last refreshed: 2 September 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01184287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing